Evolent Health/$EVH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evolent Health
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
Ticker
$EVH
Sector
Primary listing
NYSE
Employees
4,500
Headquarters
Website
Evolent Health Metrics
BasicAdvanced
$906M
-
-$1.61
0.66
-
Price and volume
Market cap
$906M
Beta
0.66
52-week high
$24.26
52-week low
$7.06
Average daily volume
2.9M
Financial strength
Current ratio
1.008
Quick ratio
0.914
Long term debt to equity
58.398
Total debt to equity
75.853
Interest coverage (TTM)
-0.24%
Profitability
EBITDA (TTM)
71.147
Gross margin (TTM)
16.36%
Net profit margin (TTM)
-5.94%
Operating margin (TTM)
-0.38%
Effective tax rate (TTM)
0.83%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-0.21%
Return on equity (TTM)
-11.04%
Valuation
Price to revenue (TTM)
0.41
Price to book
1.01
Price to tangible book (TTM)
-0.94
Price to free cash flow (TTM)
-6.403
Free cash flow yield (TTM)
-15.62%
Free cash flow per share (TTM)
-1.22
Growth
Revenue change (TTM)
-6.71%
Earnings per share change (TTM)
71.98%
3-year revenue growth (CAGR)
26.38%
10-year revenue growth (CAGR)
70.77%
3-year earnings per share growth (CAGR)
70.58%
10-year earnings per share growth (CAGR)
-22.01%
What the Analysts think about Evolent Health
Analyst ratings (Buy, Hold, Sell) for Evolent Health stock.
Bulls say / Bears say
Evolent signed five new revenue agreements in Q1 2025 expected to bring in $10 million in additional annualized revenue, demonstrating strong organic growth and solid demand from clients for its specialty care solutions.
Management reaffirmed its full-year 2025 guidance of $2.06–2.11 billion in revenue and $135–165 million in Adjusted EBITDA despite early headwinds, signaling confidence in delivering on growth and efficiency plans.
Oncology cost trends remained better than expected through May, and AI automation programs like Auth Intel are progressing well, pointing towards potential margin improvement and operational efficiency gains.
Q1 2025 revenue dropped 24% year-over-year to $483.6 million from $639.7 million in Q1 2024, as a result of contract resets and lower per-member, per-month fees, showing challenges with rate negotiations and changes in client mix.
Net loss attributable to common shareholders widened to $72.3 million in Q1 2025 from $25.2 million a year before, pushing the net loss margin to 14.9% and highlighting continued challenges to profitability.
Adjusted EBITDA margin fell to 7.6% in Q1 2025 from 8.5% a year earlier, indicating margin pressure from higher specialty care costs and significant investments in AI-driven automation.
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
Evolent Health Financial Performance
Revenues and expenses
Evolent Health Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evolent Health stock?
Evolent Health (EVH) has a market cap of $906M as of October 26, 2025.
What is the P/E ratio for Evolent Health stock?
The price to earnings (P/E) ratio for Evolent Health (EVH) stock is 0 as of October 26, 2025.
Does Evolent Health stock pay dividends?
No, Evolent Health (EVH) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next Evolent Health dividend payment date?
Evolent Health (EVH) stock does not pay dividends to its shareholders.
What is the beta indicator for Evolent Health?
Evolent Health (EVH) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.